ImmunoGen, Inc.(IMGN) Stock Research - Grey Stern Research

ImmunoGen, Inc. (IMGN) Stock Analysis

$31.24 (0.02%)

IMGN Financial Performance


Use the table below to view ImmunoGen, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $31.24 -
52 Week Low $3.61 -
52 Week High $31.25 -
Market Cap $8.7 Billion 1/16
Gross Margin 98% 2/16
Profit Margin 27% 3/16
EBITDA margin 27% 1/16
Q1 - 2024 Revenue $113.4 Million 1/16
Q1 - 2024 Earnings $30.7 Million 3/16
Q1 - 2024 Free Cash Flow $1.4 Million 3/16
Trailing 4 Quarters Revenue $329.6 Million 2/16
Trailing 4 Quarters Earnings -$18.3 Million 3/16
Quarterly Earnings Growth 175% 3/16
Annual Earnings Growth 92% 3/16
Quarterly Revenue Growth 127% 3/16
Annual Revenue Growth 90% 4/16
Cash On Hand $605.5 Million 2/16
Short Term Debt $24.9 Million 16/16
Long Term Debt $72.1 Million 8/16

ImmunoGen, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare ImmunoGen, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/16
PS 26.48 5/16
PB 15.54 4/16
PC 14.41 5/16
Liabilities to Equity 0.46 10/16
ROA -0.02 3/16
ROE -0.03 4/16
Current Ratio 3.16 6/16
Quick Ratio 2.32 6/16
Long Term Debt to Equity 0.13 9/16
Debt to Equity 0.13 9/16
Burn Rate -17.77 15/16
Cash to Cap 0.07 11/16
CCR 0.05 10/16
EV to EBITDA 267.45 2/16
EV to Revenue 24.86 5/16

Company Details

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO: Mr. Mark Enyedy

Website: https://www.immunogen.com

Address: 830 WINTER ST Boston, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Biotechnology

ImmunoGen, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to ImmunoGen, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $7.4 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
TG Therapeutics, Inc. TGTX $3.7 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $5.3 Billion
Axsome Therapeutics, Inc. AXSM $4.5 Billion
Seres Therapeutics, Inc. MCRB $152.3 Million
Hepion Pharmaceuticals, Inc. HEPA $4.3 Million
HOOKIPA Pharma Inc. HOOK $167.9 Million
PDS Biotechnology Corporation PDSB $110.5 Million
X4 Pharmaceuticals, Inc. XFOR $119.6 Million
Inozyme Pharma, Inc. INZY $376.4 Million
Elevation Oncology, Inc. ELEV $36.0 Million
Terns Pharmaceuticals, Inc. TERN $736.9 Million
eFFECTOR Therapeutics, Inc. EFTR $188,176
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
IMGN Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 113.4 Million $30.7 Million
Q2 2023 $ 83.2 Million -$4.2 Million
Q4 2023 $ 83.2 Million -$4.2 Million
Q1 2023 $ 49.9 Million -$40.6 Million
Q3 2023 $ 49.9 Million -$41.0 Million
Q4 2022 $ 41.2 Million -$59.0 Million
Q3 2022 $ 15.4 Million $1.5 Million
Q2 2022 $ 14.2 Million $590,000

View All

IMGN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $605.5 Million $822.1 Million $72.1 Million $561.6 Million
Q2 2023 $572.0 Million $714.3 Million $72.0 Million $490.8 Million
Q4 2023 $572.0 Million $714.3 Million $72.0 Million $490.8 Million
Q1 2023 $201.2 Million $288.3 Million $14.3 Million $121.9 Million
Q3 2023 $201.2 Million $288.3 Million $14.3 Million $121.9 Million
Q4 2022 $275.1 Million $348.9 Million $15.2 Million $155.8 Million
Q3 2022 $309.5 Million $358.8 Million $12.2 Million $178.0 Million
Q2 2022 $373.9 Million $422.3 Million $13.3 Million $249.8 Million

View All

IMGN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $1.4 Million -$1.4 Million $33.5 Million
Q4 2023 -$66.8 Million -$78,000 $370.7 Million
Q2 2023 -$66.8 Million -$78,000 $370.7 Million
Q1 2023 -$73.9 Million -$209,000 -$73.9 Million
Q3 2023 -$73.9 Million -$209,000 -$73.9 Million
Q4 2022 -$60.4 Million -$248,000 -$34.4 Million
Q3 2022 -$64.8 Million -$602,000 -$64.4 Million
Q2 2022 -$64.2 Million -$207,000 -$63.8 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions